Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around $2.9 ...